C Michael Cotten1, Amy P Murtha2, Ronald N Goldberg3, Chad A Grotegut2, P Brian Smith3, Ricki F Goldstein3, Kimberley A Fisher3, Kathryn E Gustafson4, Barbara Waters-Pick5, Geeta K Swamy2, Benjamin Rattray3, Siddhartha Tan6, Joanne Kurtzberg7. 1. Department of Pediatrics, Duke University, Durham, NC. Electronic address: cotte010@mc.duke.edu. 2. Department of Obstetrics and Gynecology, Duke University, Durham, NC. 3. Department of Pediatrics, Duke University, Durham, NC. 4. Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC. 5. Stem Cell Laboratory, Duke University Hospital, Durham, NC. 6. Department of Pediatrics, NorthShore University Health System and University of Chicago Pritzker School of Medicine, Chicago, IL. 7. Robertson Cell and Translational Therapy Program, Duke University, Durham, NC.
Abstract
OBJECTIVE: To assess feasibility and safety of providing autologous umbilical cord blood (UCB) cells to neonates with hypoxic-ischemic encephalopathy (HIE). STUDY DESIGN: We enrolled infants in the intensive care nursery who were cooled for HIE and had available UCB in an open-label study of non-cyropreserved autologous volume- and red blood cell-reduced UCB cells (up to 4 doses adjusted for volume and red blood cell content, 1-5 × 10(7) cells/dose). We recorded UCB collection and cell infusion characteristics, and pre- and post-infusion vital signs. As exploratory analyses, we compared cell recipients' hospital outcomes (mortality, oral feeds at discharge) and 1-year survival with Bayley Scales of Infant and Toddler Development, 3rd edition scores ≥85 in 3 domains (cognitive, language, and motor development) with cooled infants who did not have available cells. RESULTS: Twenty-three infants were cooled and received cells. Median collection and infusion volumes were 36 and 4.3 mL. Vital signs including oxygen saturation were similar before and after infusions in the first 48 postnatal hours. Cell recipients and concurrent cooled infants had similar hospital outcomes. Thirteen of 18 (74%) cell recipients and 19 of 46 (41%) concurrent cooled infants with known 1-year outcomes survived with scores >85. CONCLUSIONS: Collection, preparation, and infusion of fresh autologous UCB cells for use in infants with HIE is feasible. A randomized double-blind study is needed.
OBJECTIVE: To assess feasibility and safety of providing autologous umbilical cord blood (UCB) cells to neonates with hypoxic-ischemicencephalopathy (HIE). STUDY DESIGN: We enrolled infants in the intensive care nursery who were cooled for HIE and had available UCB in an open-label study of non-cyropreserved autologous volume- and red blood cell-reduced UCB cells (up to 4 doses adjusted for volume and red blood cell content, 1-5 × 10(7) cells/dose). We recorded UCB collection and cell infusion characteristics, and pre- and post-infusion vital signs. As exploratory analyses, we compared cell recipients' hospital outcomes (mortality, oral feeds at discharge) and 1-year survival with Bayley Scales of Infant and Toddler Development, 3rd edition scores ≥85 in 3 domains (cognitive, language, and motor development) with cooled infants who did not have available cells. RESULTS: Twenty-three infants were cooled and received cells. Median collection and infusion volumes were 36 and 4.3 mL. Vital signs including oxygen saturation were similar before and after infusions in the first 48 postnatal hours. Cell recipients and concurrent cooled infants had similar hospital outcomes. Thirteen of 18 (74%) cell recipients and 19 of 46 (41%) concurrent cooled infants with known 1-year outcomes survived with scores >85. CONCLUSIONS: Collection, preparation, and infusion of fresh autologous UCB cells for use in infants with HIE is feasible. A randomized double-blind study is needed.
Authors: F J Northington; M E Zelaya; D P O'Riordan; K Blomgren; D L Flock; H Hagberg; D M Ferriero; L J Martin Journal: Neuroscience Date: 2007-08-02 Impact factor: 3.590
Authors: Laura Bennet; Sidhartha Tan; Lotte Van den Heuij; Matthew Derrick; Floris Groenendaal; Frank van Bel; Sandra Juul; Stephen A Back; Frances Northington; Nicola J Robertson; Carina Mallard; Alistair Jan Gunn Journal: Ann Neurol Date: 2012-05 Impact factor: 10.422
Authors: Seetha Shankaran; Abbot R Laptook; Richard A Ehrenkranz; Jon E Tyson; Scott A McDonald; Edward F Donovan; Avroy A Fanaroff; W Kenneth Poole; Linda L Wright; Rosemary D Higgins; Neil N Finer; Waldemar A Carlo; Shahnaz Duara; William Oh; C Michael Cotten; David K Stevenson; Barbara J Stoll; James A Lemons; Ronnie Guillet; Alan H Jobe Journal: N Engl J Med Date: 2005-10-13 Impact factor: 91.245
Authors: N Efstathiou; V Soubasi; G Koliakos; G Kyriazis; D I Zafeiriou; A Slavakis; K Kantziou; T Pozotou; O Chatzizisi; V Drosou-Agakidou Journal: Hippokratia Date: 2015 Apr-Jun Impact factor: 0.471